HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED

Funds and ETFs Hansoh Pharmaceutical Group Company Limited

3692

KYG549581067

Name	Weight	AuM	1st Jan change	Investor Rating
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD	2.00%	4 M€	-27.92%
HAN-GINS TECH MEGATREND EQUAL WEIGHT UCITS ETF - USD	0.95%	96 M€	-3.91%
KRANESHARES EMERGING MARKET HEALTHCARE INDEX ETF - DISTRIBUTING - USD	0.92%	2 M€	-14.14%
KRANESHARES MSCI ALL CHINA HEALTH CARE INDEX UCITS ETF - USD	0.91%	2 M€	-16.59%	-
KRANESHARES MSCI CHINA ESG LEADERS UCITS ETF ACC - USD	0.30%	3 M€	-0.84%	-
KRANESHARES MSCI CHINA ESG LEADERS ETF - USD	0.23%	4 M€	-11.56%
ICBCCS S&P CHINA 500 UCITS ETF CLASS B - USD	0.06%	35 M€	-5.85%	-
GOLDMAN SACHS ACTIVEBETA EMERGING MARKETS EQUITY UCITS ETF - ACC - USD	0.03%	11 M€	+1.79%
AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF DR (D) - EUR	0.02%	441 M€	+3.02%	-
AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF DR (C) - EUR	0.02%	2,808 M€	+5.90%	-
AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF - USD	0.02%	149 M€	+0.92%	-
LEADERSHARES EQUITY SKEW ETF - USD	0.02%	117 M€	+1.36%	-
SIMPLIFY EMERGING MARKETS PLUS DOWNSIDE CONVEXITY ETF - USD	0.02%	4 M€	-4.41%	-
DAY HAGAN/NED DAVIS RESEARCH SMART SECTOR INTERNATIONAL ETF - USD	0.01%	31 M€	+3.34%	-
IMGP RBA RESPONSIBLE GLOBAL ALLOCATION ETF - USD	0.01%	7 M€	+0.11%	-
DEMOCRACY INTERNATIONAL FUND ETF - USD	0.00%	7 M€	+1.81%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR	0.00%	389 M€	+6.83%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.00%	34 M€	+4.85%	-
HORIZONS SEASONAL ROTATION ETF - CAD	0.00%	147 M€	+4.88%	-
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD	0.00%	34 M€	+2.14%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.00%	39 M€	+2.96%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - ACC - EUR	0.00%	302 M€	+3.80%	-
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.00%	17 M€	+0.50%	-
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF ACC - EUR	0.00%	108 M€	+2.03%	-
NOMURA NEXT FUNDS EMERGING MARKET EQUITY MSCI-EM (UNHEDGED) ETF - JPY	0.00%	15 M€	+11.24%

Hansoh Pharmaceutical Group Company Limited specializes in the development, manufacture and marketing of pharmaceutical products for the treatment of tumor, infectious, metabolic and autoimmune diseases. Net sales break down by revenue source as follows: - sales of pharmaceutical products (99.1%); - sales of research and development services (0.9%).

Sector

Pharmaceuticals

Calendar

2024-08-28 - Q2 2024 Earnings Release (Projected)

Related indices

HONG KONG HANG SENG

More about the company

Income Statement Evolution

More financial data

Ratings for Hansoh Pharmaceutical Group Company Limited

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.55 CNY

Average target price

17.47 CNY

Spread / Average Target

+12.35%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED	+9.26%	12.71B
ELI LILLY AND COMPANY	+26.21%	653B
NOVO NORDISK A/S	+27.00%	556B
JOHNSON & JOHNSON	-6.62%	354B
MERCK & CO., INC.	+20.47%	331B
ABBVIE INC.	+2.25%	296B
ASTRAZENECA PLC	+13.09%	233B
NOVARTIS AG	+5.46%	201B
ROCHE HOLDING AG	-9.61%	193B
AMGEN INC.	-6.25%	144B

Other Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
17.22 ^HKD	+2.50%		+9.96%	+9.26%

Apr. 03	Hansoh Pharmaceutical Secures Chinese Nod for Trial of Anti-Cancer Drug	MT
Apr. 03	Hansoh Pharmaceutical Group Company Limited, Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited Receives Grant of A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China to Be Used for the Treatment of Advanced Non-Small Cell Lung Cancer	CI